Cosmos Health CFO Georgios Terzis Buys 168,135 Shares

Georgios Terzis, CFO of Cosmos Health, bought shares worth $42,033.75.

Key Points

  • Cosmos Health CFO Georgios Terzis purchased 168,135 shares at $0.25 each on June 16, 2026, totaling $42,033.75.
  • Cosmos Health, trading at $0.2645, has a market cap of $15.52 million and a forward P/E of 3.57.
  • Other insiders, including CEO Grigorios Siokas, have also been active in buying shares of Cosmos Health recently.

Georgios Terzis, the Chief Financial Officer of Cosmos Health Inc. (NASDAQCM: COSM), recently made a significant insider purchase. On June 16, 2026, he bought 168,135 shares of the company at an average price of $0.25 per share, totaling $42,033.75. This move suggests confidence in the company's future prospects.

What Changed in Georgios Terzis's Cosmos Health Position

This insider transaction by Georgios Terzis marks a notable acquisition of shares in Cosmos Health. The purchase, made at $0.25 per share, resulted in a total investment of $42,033.75. Such insider buying can often indicate that those closest to the company see potential for growth or recovery.

Other Institutional Activity in Cosmos Health

Several institutional investors have also been adjusting their positions in Cosmos Health. Renaissance Technologies LLC increased its holdings by 55,925 shares, now holding 390,500 shares valued at approximately $123,867. Geode Capital Management, LLC significantly boosted its position by 119,427 shares, reaching a total of 318,111 shares worth around $100,916. Meanwhile, BlackRock, Inc. maintained its position with 267,797 shares valued at $84,945. Vanguard Capital Management LLC and Vanguard Fiduciary Trust Co both made new entries with 140,007 and 95,735 shares, respectively.

Cosmos Health Stock Snapshot

Shares of Cosmos Health Inc. (NASDAQCM: COSM) are currently trading around $0.2645. The company has a market capitalization of approximately $15.52 million and a forward P/E ratio of 3.57. With a beta of 4.117, the stock has shown significant volatility. Its 52-week range spans from a low of $0.193 to a high of $1.32. The stock's 50-day moving average is $0.3054, while the 200-day moving average is $0.54588. The company has a current ratio of 1.083 and a quick ratio of 0.631, indicating its short-term liquidity.

Recent Earnings

Cosmos Health reported revenue of $69.49 million, reflecting a growth rate of 30.7%. However, the company is not currently profitable, with a net margin of -30.41% and a return on equity of -92.32%. The next earnings report is anticipated on April 16, 2025.

Insider Buying and Selling at Cosmos Health Inc.

In addition to Georgios Terzis's recent purchase, other insiders have been active as well. CEO Grigorios Siokas bought 218,447 shares on June 11, 2026, at $0.21 per share, and previously acquired 701,447 shares on June 10, 2026, at $0.23 each. Secretary Demetrios Demetrios also bought 20,000 shares on May 19, 2026, at $0.28 per share. These transactions suggest strong insider confidence in the company's prospects.

About Cosmos Health

Cosmos Health Inc. is a healthcare company based in Thessaloniki, Greece. It specializes in manufacturing, developing, and trading branded nutraceutical products across various countries, including Greece, the UK, and the UAE. The company offers a range of products, such as prescription medications, over-the-counter drugs, and medical devices under the Sky Premium Life and Mediterranation brands. Led by CEO Grigorios Siokas, Cosmos Health employs around 163 people.

Bottom Line

Insider purchases like those made by Georgios Terzis often attract investor attention, as they can signal confidence in a company's future. While Cosmos Health faces challenges with profitability, the insider activity and institutional interest suggest that some see potential value. Remember, insider transactions are typically disclosed after the fact and may not reflect the current stance of the insider.

See Also

This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.